SG11201508878WA - Methods of treating cancer - Google Patents

Methods of treating cancer

Info

Publication number
SG11201508878WA
SG11201508878WA SG11201508878WA SG11201508878WA SG11201508878WA SG 11201508878W A SG11201508878W A SG 11201508878WA SG 11201508878W A SG11201508878W A SG 11201508878WA SG 11201508878W A SG11201508878W A SG 11201508878WA SG 11201508878W A SG11201508878W A SG 11201508878WA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
SG11201508878WA
Other languages
English (en)
Inventor
Julie Hambleton
Maureen R Bleam
Maurice P Deyoung
Geraldine Ferron-Brady
Rakesh Kumar
Lone Ottesen
Original Assignee
Five Prime Therapeutics Inc
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Glaxosmithkline Ip No 2 Ltd filed Critical Five Prime Therapeutics Inc
Publication of SG11201508878WA publication Critical patent/SG11201508878WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
SG11201508878WA 2013-05-01 2014-04-30 Methods of treating cancer SG11201508878WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818220P 2013-05-01 2013-05-01
US201361831029P 2013-06-04 2013-06-04
PCT/US2014/036140 WO2014179448A2 (en) 2013-05-01 2014-04-30 Methods of treating cancer

Publications (1)

Publication Number Publication Date
SG11201508878WA true SG11201508878WA (en) 2015-11-27

Family

ID=50928263

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508878WA SG11201508878WA (en) 2013-05-01 2014-04-30 Methods of treating cancer

Country Status (13)

Country Link
US (2) US20160067307A1 (enExample)
EP (1) EP2991669A2 (enExample)
JP (1) JP2016526016A (enExample)
KR (1) KR20160003141A (enExample)
CN (1) CN105188732A (enExample)
AU (1) AU2014259956A1 (enExample)
BR (1) BR112015027607A8 (enExample)
CA (1) CA2908391A1 (enExample)
HK (1) HK1213817A1 (enExample)
MX (1) MX2015015115A (enExample)
RU (1) RU2015150233A (enExample)
SG (1) SG11201508878WA (enExample)
WO (1) WO2014179448A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2012318247B2 (en) 2011-11-14 2015-12-17 Five Prime Therapeutics, Inc. Methods of treating cancer
ME03476B (me) 2013-08-01 2020-01-20 Five Prime Therapeutics Inc Nefukozilisana anti-fgfr2iiib antitijela
KR20180028524A (ko) * 2015-07-24 2018-03-16 데비오팜 인터네셔날 에스 에이 Fgfr 발현 및 fgfr 억제제에 대한 민감성
KR20250034528A (ko) * 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
PL238516B1 (pl) 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
CA3048916A1 (en) * 2017-02-06 2018-08-09 Rainier Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer
WO2018195273A1 (en) * 2017-04-19 2018-10-25 The Corporation Of Mercer University Sam-1 protein, composition and methods of use
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
WO2001075166A2 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
PL1638941T3 (pl) 2003-05-22 2010-11-30 Abbvie Bahamas Ltd Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
EP1942884A4 (en) * 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
CA2817583A1 (en) * 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) * 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
AU2012318247B2 (en) * 2011-11-14 2015-12-17 Five Prime Therapeutics, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
WO2014179448A3 (en) 2014-12-24
WO2014179448A2 (en) 2014-11-06
CA2908391A1 (en) 2014-11-06
RU2015150233A (ru) 2017-06-02
MX2015015115A (es) 2016-06-07
US20180280470A1 (en) 2018-10-04
BR112015027607A2 (pt) 2017-12-05
JP2016526016A (ja) 2016-09-01
BR112015027607A8 (pt) 2018-01-23
US20160067307A1 (en) 2016-03-10
HK1213817A1 (zh) 2016-07-15
AU2014259956A1 (en) 2015-11-12
EP2991669A2 (en) 2016-03-09
CN105188732A (zh) 2015-12-23
KR20160003141A (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL272905A (en) Methods of treating pancreatic cancer
ZA201506877B (en) Methods of treating bladder cancer
IL240935A0 (en) Methods of treating lung cancer
EP3057594A4 (en) Method of treating cancer
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
SG11201508878WA (en) Methods of treating cancer
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
IL240688A0 (en) Pancreatic cancer treatment methods
EP3008212A4 (en) Methods of treatment of cancer
EP3074040A4 (en) Method of treating cancer
HUE048625T2 (hu) Módszer rák kezelésére
ZA201507762B (en) Methods of treating cancer
GB201403083D0 (en) Treatment of cancer
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201322346D0 (en) Combination treatment of cancer
AU2013904620A0 (en) Method of treating cancer
GB201300546D0 (en) Cancer Treatment